Aurinia Pharmaceuticals Inc (AUPH) – What Are Analysts Saying About This Stock?

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $17.75.

A number of research analysts have issued reports on the stock. Zacks Research lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Weiss Ratings upgraded shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 22nd. Wall Street Zen downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Bloom Burton raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 20th. Finally, TD Cowen upped their price objective on shares of Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a research note on Wednesday, October 21st.

Aurinia Pharmaceuticals Stock Up 1.2%

AUPH opened at $17.25 on Friday. Aurinia Pharmaceuticals has a 52 week low of $11.96 and a 52 week high of $19.25. The business’s fifty day simple moving average is $16.44 and its 200 day simple moving average is $15.62.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.04. The company had revenue of $58.57 million for the quarter, compared to analysts’ expectations of $80.45 million. On average, equities analysts expect that Aurinia Pharmaceuticals will post 0.91 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in AUPH. Signaturefd LLC boosted its stake in Aurinia Pharmaceuticals by 360.0% in the 3rd quarter. Signaturefd LLC now owns 1,794 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,404 shares during the last quarter. Sterling Capital Management LLC grew its holdings in Aurinia Pharmaceuticals by 847.7% in the 3rd quarter. Sterling Capital Management LLC now owns 3,971 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 3,552 shares during the period. CWA Asset Management Group LLC grew its holdings in Aurinia Pharmaceuticals by 7.5% in the 3rd quarter. CWA Asset Management Group LLC now owns 217,590 shares of the biotechnology company’s stock valued at $3,524,000 after buying an additional 15,150 shares during the period. IFP Advisors Inc increased its stake in shares of Aurinia Pharmaceuticals by 2.0% during the 3rd quarter. IFP Advisors Inc now owns 368,966 shares of the biotechnology company’s stock valued at $5,975,000 after acquiring an additional 7,332 shares during the last quarter. Finally, State of Alaska Department of Revenue increased its stake in shares of Aurinia Pharmaceuticals by 129.1% during the 3rd quarter. State of Alaska Department of Revenue now owns 19,570 shares of the biotechnology company’s stock valued at $316,000 after acquiring an additional 11,027 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.